Rituximab for the treatment of primary membranous nephropathy

CADTH
Record ID 32018002250
English
Original Title: Rituximab to treat primary membranous nephropathy
Details
Project Status: Completed
URL for project: https://cadth.ca/rituximab-treat-primary-membranous-nephropathy
URL for protocol: https://cadth.ca/sites/default/files/pdf/ht0032-hta-retuximab-protocol.pdf
Year Published: 2022
URL for published report: https://www.cadth.ca/sites/default/files/2022-01/DRAFT_HT0032%20Rituximab%20for%20PMN%20-%20CL_Draft%20Report_0.pdf
URL for additional information: https://cadth.ca/rituximab-treat-primary-membranous-nephropathy
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Canada
MeSH Terms
  • Glomerulonephritis, Membranous
  • Rituximab
  • Nephrotic Syndrome
  • Drug Therapy
Keywords
  • Rituximab
Contact
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: <p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.